Bring It On Home

FDA Shocker: Unpacking the Controversial Drug Approval Rejection

46 min · 9 de jun de 2024
portada del episodio FDA Shocker: Unpacking the Controversial Drug Approval Rejection

Descripción

Join Daniel and Cody as they dive into the shocking news from the FDA's advisory committee review. We'll set the stage with an in-depth look at the independent panels of researchers, insurance executives, and doctors who play a crucial role in drug approval. Discover why the MAPS program, integrating psychotherapy with new drug trials, has turned the review process upside down. They'll discuss the controversies, including trial design issues, racial disparities among participants, and the surprising rejection of a breakthrough PTSD treatment. Is there a deeper bias within the FDA, or is it a matter of incompetence from the drug development team at Lycos Therapeutics?  Explore the impact on veterans and PTSD survivors, the future of therapies like MDMA and ketamine, and how companies like Healing Realty Trust are navigating these turbulent waters. Tune in for a critical analysis and personal opinions on the FDA's decision, its implications for mental health treatment, and what it means for the future of drug development and approval.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y forma parte de la comunidad de Bring It On Home!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

24 episodios

episode Ep. 25 - NAD, Psychedelics, and New Frontiers in Therapy artwork

Ep. 25 - NAD, Psychedelics, and New Frontiers in Therapy

Join us as we dive into a conversation about the benefits of NAD, the importance of clean living, and the emerging role of psychedelics in therapy. Our host shares his personal journey of going 60 days clean and the transformative effects of NAD on his physical performance. We also explore the latest news on MDMA-assisted therapy for PTSD, including congressional support and the need for proper training and planning. From the potential of psychedelic retreats to the importance of therapist-patient relationships in psychedelic therapy, this episode covers a range of topics at the intersection of wellness, mental health, and innovative treatments. Tune in to learn about the latest advancements and hear firsthand experiences that could shape the future of health and wellness.

18 de jun de 202435 min
episode FDA Shocker: Unpacking the Controversial Drug Approval Rejection artwork

FDA Shocker: Unpacking the Controversial Drug Approval Rejection

Join Daniel and Cody as they dive into the shocking news from the FDA's advisory committee review. We'll set the stage with an in-depth look at the independent panels of researchers, insurance executives, and doctors who play a crucial role in drug approval. Discover why the MAPS program, integrating psychotherapy with new drug trials, has turned the review process upside down. They'll discuss the controversies, including trial design issues, racial disparities among participants, and the surprising rejection of a breakthrough PTSD treatment. Is there a deeper bias within the FDA, or is it a matter of incompetence from the drug development team at Lycos Therapeutics?  Explore the impact on veterans and PTSD survivors, the future of therapies like MDMA and ketamine, and how companies like Healing Realty Trust are navigating these turbulent waters. Tune in for a critical analysis and personal opinions on the FDA's decision, its implications for mental health treatment, and what it means for the future of drug development and approval.

9 de jun de 202446 min